Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$45.93

-6.09 (-11.71%)

12:00
01/03/19
01/03
12:00
01/03/19
12:00

Bristol-Myers falls -11.7%

Bristol-Myers is down -11.7%, or -$6.08 to $45.94.

  • 03

    Jan

  • 03

    Jan

  • 24

    Jan

  • 28

    Jan

  • 18

    May

  • 20

    May

BMY Bristol-Myers
$45.93

-6.09 (-11.71%)

01/03/19
BARD
01/03/19
NO CHANGE
Target $92
BARD
Neutral
Baird calls Bristol-Myers buyout a 'very good deal' for Celgene
While admitting he was surprised as anyone to the news, Baird analyst Brian Skorney views the buyout by Bristol-Myers Squibb (BMY) as a "very good deal" for Celgene (CELG). The deal's success hinges on the outcome of Revlimid patent litigation, but for Celgene shareholders today, "its a big win," Skorney tells investors in a research note titled "Mega Mergers Are Back?" All told, the deal could be worth over $95 per share for Celgene, the analyst points out. With a contingent value right of $9.00 due in 2021, the analyst thinks the probability adjusted net present value of the CVR is around $5 to $6 per share. Skorney has a Neutral rating on Celgene with a $92 price target.
01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
01/03/19
PIPR
01/03/19
NO CHANGE
Target $23
PIPR
Overweight
Bristol acquisition of Celgene a positive for Fate, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes Bristol-Myers Squibb's (BMY) agreement to acquire Celgene (CELG) is in part driven by the long-term potential of cellular therapies to treat cancer. The analyst sees the deal announced this morning as a positive for Fate Therapeutics (FATE), which he notes is developing a pipeline of allogeneic and induced pluripotent stem cell natural killer and T-cell therapies. Fate is a potential acquisition target for its "rich cell therapy pipeline and platform," Tenthoff tells investors in a research note. Fate remains a top pick for Piper in 2019 and the analyst reiterates an Overweight rating on the shares with a $23 price target.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.

TODAY'S FREE FLY STORIES

SITM

SiTime

$0.00

(0.00%)

10:58
11/21/19
11/21
10:58
11/21/19
10:58
Syndicate
Breaking Syndicate news story on SiTime »

SiTime indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GRUB

GrubHub

$41.80

1.195 (2.94%)

10:55
11/21/19
11/21
10:55
11/21/19
10:55
Options
GrubHub put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITM

SiTime

$0.00

(0.00%)

10:50
11/21/19
11/21
10:50
11/21/19
10:50
Syndicate
Breaking Syndicate news story on SiTime »

SiTime indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

PAYS

Paysign

$8.71

-0.26 (-2.90%)

10:50
11/21/19
11/21
10:50
11/21/19
10:50
Hot Stocks
Aurelius says short Paysign, sees 'stock promotion set to end in failure' »

In a short report posted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 26

    Nov

DISCA

Discovery

$31.72

-0.29 (-0.91%)

10:46
11/21/19
11/21
10:46
11/21/19
10:46
Hot Stocks
Discovery shares 'dramatically undervalued,' says John Malone »

John Malone, asked during…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$10.94

-0.105 (-0.95%)

10:45
11/21/19
11/21
10:45
11/21/19
10:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
11/21/19
11/21
10:45
11/21/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
11/21/19
11/21
10:45
11/21/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
11/21/19
11/21
10:45
11/21/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

10:45
11/21/19
11/21
10:45
11/21/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

CAN

Canaan

$0.00

(0.00%)

10:44
11/21/19
11/21
10:44
11/21/19
10:44
Syndicate
Breaking Syndicate news story on Canaan »

Canaan opens at $12.60,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

10:44
11/21/19
11/21
10:44
11/21/19
10:44
Periodicals
Breaking Periodicals news story on We Company, SoftBank, SoftBank »

WeWork to cut 2,400 jobs…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITM

SiTime

$0.00

(0.00%)

10:42
11/21/19
11/21
10:42
11/21/19
10:42
Syndicate
SiTime indicated to open at $17.25, IPO priced at $13.00 »

SiTime (SITM) priced 4.3M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CAN

Canaan

$0.00

(0.00%)

10:41
11/21/19
11/21
10:41
11/21/19
10:41
Syndicate
Breaking Syndicate news story on Canaan »

Canaan indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

10:35
11/21/19
11/21
10:35
11/21/19
10:35
General news
U.S. existing home sales tracked estimates »

U.S. existing home sales…

TSLA

Tesla

$357.27

4.94 (1.40%)

, GM

General Motors

$35.16

-0.1 (-0.28%)

10:34
11/21/19
11/21
10:34
11/21/19
10:34
On The Fly
Wall Street eyes Tesla ahead of 'Cybertruck' pickup truck reveal »

Shares of Tesla (TSLA)…

TSLA

Tesla

$357.27

4.94 (1.40%)

GM

General Motors

$35.16

-0.1 (-0.28%)

F

Ford

$8.72

-0.005 (-0.06%)

AMZN

Amazon.com

$1,738.96

-6.54 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 04

    Feb

CAN

Canaan

$0.00

(0.00%)

10:32
11/21/19
11/21
10:32
11/21/19
10:32
Syndicate
Canaan indicated to open at $12.60, IPO priced at $9.00 »

Canaan (CAN) priced 10M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

10:30
11/21/19
11/21
10:30
11/21/19
10:30
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

VKTX

Viking Therapeutics

$7.20

0.12 (1.69%)

10:30
11/21/19
11/21
10:30
11/21/19
10:30
Recommendations
Viking Therapeutics analyst commentary  »

Viking posting for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$310.33

-0.47 (-0.15%)

10:30
11/21/19
11/21
10:30
11/21/19
10:30
Options
Put sales in SP500 ETF likely unwind hedges from August »

Put sales in SP500 ETF…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USO

United States Oil Fund

$12.11

0.2 (1.68%)

10:30
11/21/19
11/21
10:30
11/21/19
10:30
General news
EIA natural gas storage change for week ending November 15 »

Gas inventories 94 Bcf…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
11/21/19
11/21
10:25
11/21/19
10:25
Hot Stocks
Breaking Hot Stocks news story  »

Civista Bancshares…

SNAP

Snap

$15.56

0.245 (1.60%)

10:25
11/21/19
11/21
10:25
11/21/19
10:25
Options
Snap Inc. call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

10:25
11/21/19
11/21
10:25
11/21/19
10:25
General news
Treasury Action: Treasuries have continued to give ground »

Treasury Action:…

TRIP

TripAdvisor

$28.18

0.22 (0.79%)

10:25
11/21/19
11/21
10:25
11/21/19
10:25
Conference/Events
TripAdvisor to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 25

    Nov

  • 26

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.